Asset Details
Do you wish to reserve the book?
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Do you wish to request the book?
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
2017
Overview
In a phase 2 trial involving 166 patients with moderate-to-severe plaque psoriasis, risankizumab, a humanized monoclonal antibody that selectively inhibits IL-23, achieved clinical response superior to that achieved with ustekinumab, an IL-12 and IL-23 inhibitor.
Psoriasis is a chronic immune-mediated inflammatory skin disease that occurs in 2% of adults; it has a substantial effect on quality of life and is associated with obesity, hypertension, diabetes mellitus, hypercholesterolemia, and the metabolic syndrome.
1
–
4
The proinflammatory cytokine interleukin-23 is thought to play a pivotal role in the pathogenesis of psoriasis by inducing and maintaining T helper (Th) 17 cells, Th22 cells, innate lymphoid cells, and the effector cytokines interleukin-17, interleukin-22, and tumor necrosis factor (TNF) α.
5
–
9
Interleukin-23 is composed of two subunits, p19 and p40. The p19 subunit is unique to interleukin-23, whereas the p40 subunit . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - therapeutic use
/ Dermatologic Agents - adverse effects
/ Dermatologic Agents - therapeutic use
/ Female
/ Humans
/ Interleukin-12 - antagonists & inhibitors
/ Interleukin-23 - antagonists & inhibitors
/ Male
/ Skin
